UNSPSC 51332005: Zetidoline

This classification denotes an antipsychotic agent with the molecular formula C16H22ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3B5J9TG94X, chemically known as 2-imidazolidinone, 1-(3-chlorophenyl)-3-(2-(3,3-dimethyl-1-azetidinyl)ethyl)- but generally known as zetidoline, which bears US NIH Compound Identifier 72155. European Medicines Agency schedules Zetidoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00149MIG.

UNSPSC 51332005 Zetidoline is a Commodity code that nominally describes a specific pharmaceutical agent, but recent state and local procurement activity under this code shows minimal direct correlation to the code's technical scope. The recent opportunities solicited include naloxone and drug deactivation systems for emergency response and community health, a request for information on direct-to-manufacturer pharmacy prescription programs, and generic multi-source pharmaceuticals and over-the-counter products distributed through cooperative purchasing. These three activities span emergency medical supplies, pharmacy benefit program design, and bulk pharmaceutical distribution — none of which cleanly align with zetidoline as a single-agent therapeutic product. The issuing bodies represent a mix of county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Oregon and other participating jurisdictions). This fragmentation across health system procurement channels suggests the code may be a miscategorization or a catch-all for diverse pharmaceutical procurement rather than a focused commodity track.

Geographic activity spans Florida, Texas, Minnesota, and Oregon based on recent postings. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription contracting strategies; and Minnesota's MMCAP RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products supplied through authorized wholesalers. The code shows limited recent activity genuinely focused on zetidoline itself; pursuit under this code should be informed by clarification of whether the actual commodity being bought matches the code assignment or whether a recoded opportunity lies elsewhere in the pharmaceutical supply taxonomy.